Novavax, Inc.
22.08.2013 08:00
---------------------------------------------------------------------------
ROCKVILLE, Md., 2013-08-22 08:00 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX) announced today the number of shares tendered to it
during the extended acceptance period for its recommended public offer to
acquire all issued and outstanding shares and warrants (warrants series 2005-I
and 2005-II) of Isconova AB ('Isconova'), which was first communicated on June
4, 2013, (the 'Offer'), and which was extended to August 20, 2013.
As of July 30, 2013, approximately 12,152,077 shares and all warrants issued by
Isconova, corresponding to approximately 97.4 per cent of the shares and 100
per cent of the warrants issued by Isconova, respectively, had been validly
tendered and not properly withdrawn.
On July 31, 2013, Novavax declared the Offer unconditional and completed the
Offer in relation to securities tendered through July 30, 2013. Novavax also
extended the acceptance period in the Offer, which expired on 24:00, Central
European Summer Time (6:00 pm Eastern Time) on August 20, 2013.
During the extended acceptance period, approximately 258,051 shares issued by
Isconova, corresponding to approximately 2.1 per cent of the shares issued by
Isconova, were validly tendered and not properly withdrawn. Together with the
97.4 per cent of shares and 100 per cent of warrants tendered during the
initial acceptance period, approximately 99.5 per cent of the shares and 100
per cent of the warrants issued by Isconova were validly tendered and not
properly withdrawn during the Offer. Novavax will not make any additional
extension of the acceptance period.
Settlement for shares tendered during the extended acceptance period is
expected to begin on or before August 27, 2013.
Novavax did not hold any shares or warrants in Isconova prior to the
announcement of the Offer and has not acquired any shares or warrants in
Isconova outside the Offer.
Advisors
Ropes & Gray LLP and Setterwalls Advokatbyra AB are Novavax' legal advisors in
conjunction with the offer. Pareto Ohman AB is Novavax' financial advisor in
conjunction with the Offer.
Handelsbanken Capital Markets is Isconova's financial advisor in conjunction
with the Offer. Advokatfirman Lindahl KB is Isconova's legal advisors in
conjunction with the Offer.
This information was made public on August 22, 2013, at 08:00 CET.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines to address a broad range of infectious diseases worldwide.
Using innovative recombinant nanoparticle technology, as well as new and
efficient manufacturing approaches, the company produces vaccine candidates to
combat diseases, with the goal of allowing countries to better prepare for and
more effectively respond to rapidly spreading infections. Novavax is committed
to using its technology platform to create geographic-specific vaccine
solutions and is therefore involved in several international partnerships,
including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences
of Korea and PATH. Together, these organizations support Novavax' worldwide
commercialization strategy and have the global reach to create real and lasting
change in the biopharmaceutical field. Additional information about Novavax is
available on the company's website, novavax.com.
CONTACT: John A. Herrmann
VP, General Counsel and Secretary
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
22.08.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Novavax Acquires Isconova; Extended Public Tender Offer Period Closed
| Source: EQS Group AG